Pharmaceutical company bonds, the most expensive in the U.S. corporate credit market, face rating cuts after a buyout spree to replace expiring patents more than doubled their debt to $270 billion from 2006.
Pharmaceutical company bonds, the most expensive in the U.S. corporate credit market, face rating cuts after a buyout spree to replace expiring patents more than doubled their debt to $270 billion from 2006.
Market Data 
Markets 
AI
